310 related articles for article (PubMed ID: 14741033)
1. Blood-brain barrier permeation models: discriminating between potential CNS and non-CNS drugs including P-glycoprotein substrates.
Adenot M; Lahana R
J Chem Inf Comput Sci; 2004; 44(1):239-48. PubMed ID: 14741033
[TBL] [Abstract][Full Text] [Related]
2. Progress in brain penetration evaluation in drug discovery and development.
Liu X; Chen C; Smith BJ
J Pharmacol Exp Ther; 2008 May; 325(2):349-56. PubMed ID: 18203948
[TBL] [Abstract][Full Text] [Related]
3. Applications of a blood-brain barrier technology platform to predict CNS penetration of various chemotherapeutic agents. 1. Anti-infective drugs.
Adenot M; Perriere N; Scherrmann JM; Lahana R
Chemotherapy; 2007; 53(1):70-2. PubMed ID: 17202814
[TBL] [Abstract][Full Text] [Related]
4. Central nervous system penetration for small molecule therapeutic agents does not increase in multiple sclerosis- and Alzheimer's disease-related animal models despite reported blood-brain barrier disruption.
Cheng Z; Zhang J; Liu H; Li Y; Zhao Y; Yang E
Drug Metab Dispos; 2010 Aug; 38(8):1355-61. PubMed ID: 20427691
[TBL] [Abstract][Full Text] [Related]
5. Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs.
Mahar Doan KM; Humphreys JE; Webster LO; Wring SA; Shampine LJ; Serabjit-Singh CJ; Adkison KK; Polli JW
J Pharmacol Exp Ther; 2002 Dec; 303(3):1029-37. PubMed ID: 12438524
[TBL] [Abstract][Full Text] [Related]
6. In vitro P-glycoprotein assays to predict the in vivo interactions of P-glycoprotein with drugs in the central nervous system.
Feng B; Mills JB; Davidson RE; Mireles RJ; Janiszewski JS; Troutman MD; de Morais SM
Drug Metab Dispos; 2008 Feb; 36(2):268-75. PubMed ID: 17962372
[TBL] [Abstract][Full Text] [Related]
7. Development and validation of a pharmacophore-based QSAR model for the prediction of CNS activity.
Gozalbes R; Barbosa F; Nicolaï E; Horvath D; Froloff N
ChemMedChem; 2009 Feb; 4(2):204-9. PubMed ID: 19097128
[TBL] [Abstract][Full Text] [Related]
8. Role of drug efflux transporters in the brain for drug disposition and treatment of brain diseases.
Löscher W; Potschka H
Prog Neurobiol; 2005 May; 76(1):22-76. PubMed ID: 16011870
[TBL] [Abstract][Full Text] [Related]
9. In vitro P-glycoprotein efflux ratio can predict the in vivo brain penetration regardless of biopharmaceutics drug disposition classification system class.
Kikuchi R; de Morais SM; Kalvass JC
Drug Metab Dispos; 2013 Dec; 41(12):2012-7. PubMed ID: 24009309
[TBL] [Abstract][Full Text] [Related]
10. Functional characterization and comparison of the outer blood-retina barrier and the blood-brain barrier.
Steuer H; Jaworski A; Elger B; Kaussmann M; Keldenich J; Schneider H; Stoll D; Schlosshauer B
Invest Ophthalmol Vis Sci; 2005 Mar; 46(3):1047-53. PubMed ID: 15728564
[TBL] [Abstract][Full Text] [Related]
11. Blood-brain barrier in vitro models as tools in drug discovery: assessment of the transport ranking of antihistaminic drugs.
Neuhaus W; Mandikova J; Pawlowitsch R; Linz B; Bennani-Baiti B; Lauer R; Lachmann B; Noe CR
Pharmazie; 2012 May; 67(5):432-9. PubMed ID: 22764578
[TBL] [Abstract][Full Text] [Related]
12. Delivery of therapeutic agents to the central nervous system: the problems and the possibilities.
Begley DJ
Pharmacol Ther; 2004 Oct; 104(1):29-45. PubMed ID: 15500907
[TBL] [Abstract][Full Text] [Related]
13. Potential of biopartitioning micellar chromatography as an in vitro technique for predicting drug penetration across the blood-brain barrier.
Escuder-Gilabert L; Molero-Monfort M; Villanueva-Camañas RM; Sagrado S; Medina-Hernández MJ
J Chromatogr B Analyt Technol Biomed Life Sci; 2004 Aug; 807(2):193-201. PubMed ID: 15203029
[TBL] [Abstract][Full Text] [Related]
14. In silico prediction of central nervous system activity of compounds. Identification of potential pharmacophores by the TOPS-MODE approach.
Cabrera Pérez MA; Sanz MB
Bioorg Med Chem; 2004 Nov; 12(22):5833-43. PubMed ID: 15498659
[TBL] [Abstract][Full Text] [Related]
15. Applications of a blood-brain barrier technology platform to predict CNS penetration of various chemotherapeutic agents. 2. Cationic peptide vectors for brain delivery.
Adenot M; Merida P; Lahana R
Chemotherapy; 2007; 53(1):73-6. PubMed ID: 17202815
[TBL] [Abstract][Full Text] [Related]
16. Prediction of CNS activity of compound libraries using substructure analysis.
Engkvist O; Wrede P; Rester U
J Chem Inf Comput Sci; 2003; 43(1):155-60. PubMed ID: 12546548
[TBL] [Abstract][Full Text] [Related]
17. Drug delivery and in vitro models of the blood-brain barrier.
Cucullo L; Aumayr B; Rapp E; Janigro D
Curr Opin Drug Discov Devel; 2005 Jan; 8(1):89-99. PubMed ID: 15679176
[TBL] [Abstract][Full Text] [Related]
18. A new blood-brain barrier model using primary rat brain endothelial cells, pericytes and astrocytes.
Nakagawa S; Deli MA; Kawaguchi H; Shimizudani T; Shimono T; Kittel A; Tanaka K; Niwa M
Neurochem Int; 2009; 54(3-4):253-63. PubMed ID: 19111869
[TBL] [Abstract][Full Text] [Related]
19. In vitro models for the blood-brain barrier.
Garberg P; Ball M; Borg N; Cecchelli R; Fenart L; Hurst RD; Lindmark T; Mabondzo A; Nilsson JE; Raub TJ; Stanimirovic D; Terasaki T; Oberg JO; Osterberg T
Toxicol In Vitro; 2005 Apr; 19(3):299-334. PubMed ID: 15713540
[TBL] [Abstract][Full Text] [Related]
20. Potential prodrugs of non-steroidal anti-inflammatory agents for targeted drug delivery to the CNS.
Perioli L; Ambrogi V; Bernardini C; Grandolini G; Ricci M; Giovagnoli S; Rossi C
Eur J Med Chem; 2004 Aug; 39(8):715-27. PubMed ID: 15276305
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
